Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
100 hedge funds and large institutions have $835M invested in Infinity Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 50 increasing their positions, 36 reducing their positions, and 23 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 36
26% more call options, than puts
Call options by funds: $19.1M | Put options by funds: $15.2M
10% more capital invested
Capital invested by funds: $762M → $835M (+$73.4M)
16% less funds holding
Funds holding: 119 → 100 (-19)
74% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$43M |
| 2 |
Millennium Management
New York
|
+$14M |
| 3 |
Goldman Sachs
New York
|
+$9.12M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$6.7M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$9.72M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.66M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$8.22M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$6.85M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.85M |
INFI Hedge Fund Activity: Q3 2013 in Review
100 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2013, worth a combined $835M — up 9.6% from $762M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of INFI and 6 opened new positions — a net loss of 17 holders — while 36 trimmed existing stakes and 50 added.
The largest buyer was SAC Capital Advisors, adding an estimated $43M. The largest seller was Oxford Asset Management, cutting an estimated $9.72M.
- 100 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2013, down from 119 in Q2 2013.
- Funds reported $835M of Infinity Pharmaceuticals, Inc. stock for Q3 2013, up 9.6% quarter-over-quarter.
- 6 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2013 and 23 closed out, a net change of -17 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2013 was SAC Capital Advisors, an estimated $43M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q3 2013 was Oxford Asset Management, an estimated $9.72M sold.
Based on aggregated 13F filings for Q3 2013.